{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:39:16Z","timestamp":1785278356511,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.jhep.2007.01.003","type":"journal-article","created":{"date-parts":[[2007,1,27]],"date-time":"2007-01-27T07:13:47Z","timestamp":1169882027000},"page":"734-742","source":"Crossref","is-referenced-by-count":131,"title":["Hepatology may have problems with putative surrogate outcome measures"],"prefix":"10.1016","volume":"46","author":[{"given":"Christian","family":"Gluud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Brok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Koretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2007.01.003_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials (definition and operational criteria)","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomised experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"10.1016\/j.jhep.2007.01.003_bib3","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/sim.923","article-title":"Evaluation of surrogate end-points in randomized experiments with mixed discrete and continuous outcomes","volume":"20","author":"Molenberghs","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.0006-341X.2004.00239.x","article-title":"Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach","volume":"60","author":"Alonso","year":"2004","journal-title":"Biometrics"},{"key":"10.1016\/j.jhep.2007.01.003_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/sim.2315","article-title":"A unifying approach for surrogate marker validation based on Prentice\u2019s criteria","volume":"25","author":"Alonso","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib6","series-title":"The evaluation of surrogate endpoints","author":"Burzykowski","year":"2005"},{"key":"10.1016\/j.jhep.2007.01.003_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarker Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2007.01.003_bib8","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1","article-title":"Estimating the proportion of treatment effect explained by a surrogate marker","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib9","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1002\/sim.1575","article-title":"Proportion of treatment effect (PTE) explained by a surrogate marker","volume":"22","author":"Chen","year":"2003","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib10","unstructured":"Note for guidance on general considerations for clinical trials (CPMP\/ICH\/291\/95). ICH Topic E 8: general considerations for clinical trials, <http:\/\/www.emea.europa.eu\/pdfs\/human\/ich\/029195en.pdf>; 2006 [accessed 30.11.06]."},{"key":"10.1016\/j.jhep.2007.01.003_bib11","unstructured":"US Department of Health and Human Services: FDA: The Nation\u2019s Premier Consumer Health Protection Agency, in US Food and Drug Administration, <http:\/\/www.fda.gov\/oc\/opacom\/brochure\/Healthbro.pdf> (FDA 01-1316); 2004 [accessed 30.11.06]."},{"key":"10.1016\/j.jhep.2007.01.003_bib12","unstructured":"US Department of Health and Human Services: Guidance for Industry: Fast Track Drug Development Programs-Designation, Development, and Application Review, in, Food and Drug Administration, <http:\/\/www.fda.gov\/cder\/guidance\/index.htm>; 2004 [accessed 30.11.06]."},{"key":"10.1016\/j.jhep.2007.01.003_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","article-title":"Biomarkers and surrogate markers: an FDA perspective","volume":"1","author":"Katz","year":"2004","journal-title":"NeuroRx\u00ae: J Am Soc Exp NeuroTher"},{"key":"10.1016\/j.jhep.2007.01.003_bib14","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.295.19.2270","article-title":"Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organisations: 2000\u20132005","volume":"295","author":"Ridker","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2007.01.003_bib15","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1371\/journal.pmed.0030451","article-title":"Educating health professionals about drug and device promotion: advocates\u2019 recommendations","volume":"3","author":"Mansfield","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jama.284.10.1290","article-title":"Users\u2019 guides to the medical literature: XXV. Evidence-based medicine: principles for applying the users\u2019 guides to patient care. Evidence-Based Medicine Working Group","volume":"284","author":"Guyatt","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2007.01.003_bib17","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.281.19.1836","article-title":"Users\u2019 guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group","volume":"281","author":"Guyatt","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2007.01.003_bib18","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1001\/jama.270.21.2598","article-title":"Users\u2019 guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group","volume":"270","author":"Guyatt","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2007.01.003_bib19","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses","volume":"135","author":"Kjaergard","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/aje\/kwj069","article-title":"Bias in clinical intervention research","volume":"163","author":"Gluud","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2007.01.003_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2005.12.006","article-title":"The culture of designing hepato-biliary randomised trials","volume":"44","author":"Gluud","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2007.01.003_bib22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","article-title":"Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review","volume":"131","author":"D\u2019Amico","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2007.01.003_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate outcome measures in clinical trials (Are we being misled?)","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users\u2019 guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group","volume":"282","author":"Bucher","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2007.01.003_bib25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Preliminary report (effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction)","volume":"321","author":"The Cardiac Arrhythmia Suppression Trial (CAST) Investigators","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib26","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/0002-9149(90)91287-G","article-title":"The cardiac arrhythmia suppression trial (background, interim results and implications)","volume":"65","author":"Pratt","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jhep.2007.01.003_bib27","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.282.8.786","article-title":"Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease","volume":"282","author":"Psaty","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2007.01.003_bib28","series-title":"Excess mortality estimates. Deadly medicine: Why tens of thousands of heart patients died in America\u2019s worst drug disaster","author":"Moore","year":"1995"},{"key":"10.1016\/j.jhep.2007.01.003_bib29","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.01.003_bib30","unstructured":"Proceedings of the Consensus Conference on Hepatitis C. April 21\u201322; 2004, Edinburgh, United Kingdom. J Viral Hepat 2004;11:1\u20134."},{"key":"10.1016\/j.jhep.2007.01.003_bib31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.01.003_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archinte.165.19.2206","article-title":"Effects of adding ribavirin to interferon to treat chronic hepatitis C infection","volume":"165","author":"Brok","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib33","doi-asserted-by":"crossref","unstructured":"Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev 2005, Issue 2. Art. No.: CD005445. doi:10.1002\/14651858.CD005445.","DOI":"10.1002\/14651858.CD005445"},{"key":"10.1016\/j.jhep.2007.01.003_bib34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2006.07.007","article-title":"Endpoints for clinical trials on treatment of hepatitis C","volume":"45","author":"Kang","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2007.01.003_bib35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/hep.20518","article-title":"Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis","volume":"41","author":"Radkowski","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.01.003_bib36","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gut.2003.038257","article-title":"Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy","volume":"53","author":"Veldt","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2007.01.003_bib37","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.3748\/wjg.v12.i34.5532","article-title":"Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment","volume":"12","author":"Chavalitdhamrong","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2007.01.003_bib38","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1002\/hep.1840360718","article-title":"Treatment of chronic hepatitis C: a systematic review","volume":"36","author":"Chander","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.01.003_bib39","unstructured":"Simin M, Brok J, Stimac D, Gluud LL, Gluud C. Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin. Aliment Pharmacol Ther 2007, in press."},{"key":"10.1016\/j.jhep.2007.01.003_bib40","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/gast.2002.34785","article-title":"Interferon therapy prolonged life expectancy among chronic hepatitis C patients","volume":"123","author":"Yoshida","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2007.01.003_bib41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/jhep.2003.50329","article-title":"Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study","volume":"38","author":"Imazeki","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.01.003_bib42","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2004.05.019","article-title":"Evaluation of amantadine in chronic hepatitis C: a meta-analysis","volume":"41","author":"Deltenre","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2007.01.003_bib43","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2006.08.027","article-title":"Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha","volume":"131","author":"Henry","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2007.01.003_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0676.1996.tb00729.x","article-title":"A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C","volume":"16","author":"Andreone","year":"1996","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2007.01.003_bib45","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1572-0241.2006.00505.x","article-title":"Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials","volume":"101","author":"Brok","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2007.01.003_bib46","doi-asserted-by":"crossref","unstructured":"Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev 2002, Issue 2. Art. No.: CD000370. doi:10.1002\/14651858.CD000370.","DOI":"10.1002\/14651858.CD000370"},{"key":"10.1016\/j.jhep.2007.01.003_bib47","first-page":"3216","article-title":"Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group","volume":"46","author":"Bernardinello","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2007.01.003_bib48","first-page":"302","article-title":"Hepatocarcinoma in HCV compensated correlated liver cirrhosis: role of treatment with interferon","volume":"93","author":"Testino","year":"2002","journal-title":"Recenti Prog Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib49","first-page":"1154","article-title":"Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C","volume":"52","author":"Soga","year":"2005","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jhep.2007.01.003_bib50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(00)03595-9","article-title":"Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis","volume":"357","author":"Nishiguchi","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2007.01.003_bib51","doi-asserted-by":"crossref","unstructured":"Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2001, Issue 4. Art. No.: CD000551. doi:10.1002\/14651858.CD000551.","DOI":"10.1002\/14651858.CD000551"},{"key":"10.1016\/j.jhep.2007.01.003_bib52","doi-asserted-by":"crossref","unstructured":"Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2007 [in press].","DOI":"10.1002\/14651858.CD006000.pub2"},{"key":"10.1016\/j.jhep.2007.01.003_bib53","doi-asserted-by":"crossref","unstructured":"Gong Y, Frederiksen SL, Gluud C. d-penicillamine for primary biliary cirrhosis. Cochrane Database Syst Rev 2004, Issue 4. Art. No.: CD004789. doi:10.1002\/14651858.CD004789.pub2.","DOI":"10.1002\/14651858.CD004789.pub2"},{"key":"10.1016\/j.jhep.2007.01.003_bib54","doi-asserted-by":"crossref","unstructured":"Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev 2004, Issue 2. Art. No.: CD004481. doi:10.1002\/14651858.CD004481.pub2.","DOI":"10.1002\/14651858.CD004481.pub2"},{"key":"10.1016\/j.jhep.2007.01.003_bib55","doi-asserted-by":"crossref","unstructured":"Gong Y, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 2005, Issue 3. Art. No.: CD004385. doi:10.1002\/14651858.CD004385.pub2.","DOI":"10.1002\/14651858.CD004385.pub2"},{"key":"10.1016\/j.jhep.2007.01.003_bib56","doi-asserted-by":"crossref","unstructured":"Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. (Protocol) Cochrane Database Syst Rev 2006, Issue 2. Art. No.: CD006000. doi:10.1002\/14651858.CD006000.","DOI":"10.1002\/14651858.CD006000"},{"key":"10.1016\/j.jhep.2007.01.003_bib57","doi-asserted-by":"crossref","unstructured":"Gong Y, Christensen E, Gluud C. Cyclosporin A for primary biliary cirrhosis. (Protocol) Cochrane Database Syst Rev 2005, Issue 4. Art. No.: CD005526. doi:10.1002\/14651858.CD005526.","DOI":"10.1002\/14651858.CD005526"},{"key":"10.1016\/j.jhep.2007.01.003_bib58","unstructured":"Gong Y. Interventions for patients with primary biliary cirrhosis. Systematic reviews with meta-analysis of randomised clinical trials assessing ursodeoxycholic acid and immunosuppressants. Ph.D. thesis. University of Copenhagen [in press]."},{"key":"10.1016\/j.jhep.2007.01.003_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.01.003_bib60","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2007.01.003_bib61","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jama.1936.02770060032009","article-title":"Percentage of weight loss. A basic indicator of surgical risk in patients with chronic peptic ulcer","volume":"106","author":"Studley","year":"1936","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2007.01.003_bib62","series-title":"Clinical nutrition","first-page":"122","article-title":"Caloric deficiency and starvation","author":"Keys","year":"1962"},{"key":"10.1016\/j.jhep.2007.01.003_bib63","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJM198204223061606","article-title":"Nutritional assessment. A comparison of clinical judgement and objective measurements","volume":"306","author":"Baker","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0002-9610(80)90246-9","article-title":"Prognostic nutritional index in gastrointestinal surgery","volume":"139","author":"Buzby","year":"1980","journal-title":"Am J Surg"},{"key":"10.1016\/j.jhep.2007.01.003_bib65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0148607180004004357","article-title":"Incidence and mortality of hypoalbuminemic patients in hospitalized veterans","volume":"4","author":"Reinhardt","year":"1980","journal-title":"JPEN"},{"key":"10.1016\/j.jhep.2007.01.003_bib66","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0016-5085(01)92000-1","article-title":"AGA technical review \u2013 parenteral nutrition","volume":"121","author":"Koretz","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2007.01.003_bib67","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1572-0241.2006.01024.x","article-title":"Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials","volume":"102","author":"Koretz","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2007.01.003_bib68","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1079\/PNS2005433","article-title":"Nutrition society symposium on \u2018End points in clinical nutrition trials\u2019. Death, morbidity and economics are the only end points for trials","volume":"64","author":"Koretz","year":"2005","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.jhep.2007.01.003_bib69","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jhep.2005.06.017","article-title":"Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews","volume":"43","author":"K\u00fcrstein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2007.01.003_bib70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.ajkd.2006.03.044","article-title":"Surrogate markers in clinical studies: problems solved or created?","volume":"48","author":"Manns","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jhep.2007.01.003_bib71","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/00019053-200523030-00001","article-title":"EMEA: For patients or for industry?","volume":"23","author":"Garattini","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jhep.2007.01.003_bib72","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.bjc.6602750","article-title":"Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures","volume":"93","author":"Apolone","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2007.01.003_bib73","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2125.2006.02579.x","article-title":"Orphan drug development is progressing too slowly","volume":"61","author":"Joppi","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2007.01.003_bib74","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-006-0629-3","article-title":"CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?","author":"Barbui","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jhep.2007.01.003_bib75","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMsb053432","article-title":"Reform of drug regulation \u2013 beyond an independent drug-safety board","volume":"354","author":"Ray","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2007.01.003_bib76","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1056\/NEJMp068197","article-title":"Surviving sepsis\u2013practice guidelines, marketing campaigns, and Eli Lilly","volume":"355","author":"Eichacker","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827807000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827807000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T21:05:18Z","timestamp":1556053518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827807000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0168827807000396"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2007.01.003","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}